Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Tumors of the Central Nervous System, Volume 2

Gliomas: Glioblastoma (Part 2)

  • Book
  • © 2011

Overview

Editors:
  1. M.A. Hayat

    1. , Kean University, Room 213, Library building, Union, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Targeted therapy determined by molecular genetics is emphasized.
  • Several imaging techniques for diagnosis and treatment assessment are detailed.
  • Present and future therapeutic drugs against malignant gliomas are described.
  • The anti-tumor action of cyclosporine A and functionally-related drugs is explained.
  • Brain tumor angiogenesis and glioma grading are described.

Part of the book series: Tumors of the Central Nervous System (TCNS, volume 2)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (42 chapters)

  1. Front Matter

    Pages i-xxi
    Download chapter PDF

  2. Introduction

    • M.A. Hayat
    Pages 1-7

  3. Biomarkers and Diagnosis

    1. Front Matter

      Pages 9-9
      Download chapter PDF

  4. Biomarkers And Diagnosis

    1. Gliomagenesis: Advantages and Limitations of Biomarkers

      • Michel Wager, Lucie Karayan-Tapon, Christian-Jacques Larsen
      Pages 11-24

    2. Molecular Subtypes of Gliomas

      • Lonneke A.M. Gravendeel, Pim J. French
      Pages 25-29

    3. Glioblastoma: Germline Mutation of TP53

      • Haruhiko Sugimura, Hidetaka Yamada, Shinji Kageyama, Yasuhiro Yamamura, Naoki Yokota, Hiroki Mori et al.
      Pages 31-38

    4. Familial Gliomas: Role of TP53 Gene

      • Soufiane El Hallani, Ilham Ratbi
      Pages 39-45

    5. The Role of IDH1 and IDH2 Mutations in Malignant Gliomas

      • Yukihiko Sonoda, Ichiyo Shibahara, Ryuta Saito, Toshihiro Kumabe, Teiji Tominaga
      Pages 47-52

    6. Malignant Glioma: Isocitrate Dehydrogenases 1 and 2 Mutations

      • Zachary J. Reitman, Hai Yan
      Pages 53-62

    7. Metabolic Differences in Different Regions of Glioma Samples

      • Francisca M. Santandreu, Jordi Oliver, Pilar Roca
      Pages 63-72

    8. Glioblastoma Patients: Role of Methylated MGMT

      • Giulio Metro, Alessandra Fabi
      Pages 73-79

    9. Brain Tumor Angiogenesis and Glioma Grading: Role of Tumor Blood Volume and Permeability Estimates Using Perfusion CT

      • Rajan Jain
      Pages 81-91

    10. Vasculogenic Mimicry in Glioma

      • Zhong-Ping Chen, Yin-Sheng Chen
      Pages 93-101

    11. Newly Diagnosed Glioma: Diagnosis Using Positron Emission Tomography with Methionine and Fluorothymidine

      • Nobuyuki Kawai, Yoshihiro Nishiyama, Takashi Tamiya
      Pages 103-112

    12. Role of Diffusion Tensor Imaging in Differentiation of Glioblastomas from Solitary Brain Metastases

      • Sumei Wang, Harish Poptani, Elias R. Melhem, Sungheon Kim
      Pages 113-121

    13. 131I-TM-601 SPECT imaging of Human Glioma

      • Adam N. Mamelak, David Hockaday
      Pages 123-130

    14. Assessment of Biological Target Volume Using Positron Emission Tomography in High-Grade Glioma Patients

      • Habib Zaidi, Srinivasan Senthamizhchelvan
      Pages 131-141

    15. Skin Metastases of Glioblastoma

      • Rebecca Senetta, Paola Cassoni
      Pages 143-149

  5. Therapy

    1. Front Matter

      Pages 151-151
      Download chapter PDF

    2. Diffuse Low-Grade Gliomas: What Does “Complete Resection” Mean?

      • Johan Pallud
      Pages 153-161
Back to top

Keywords

About this book

Advantages and limitations of biomarkers in gliomagenesis are described. Molecular subtypes of gliomas are detailed. The role played by TP53 gene mutation in the deadliest brain tumor, glioblastoma multiforme, is pointed out. The role of mutations of IDH1 and IDH2, and isocitrate dehydrogenases in malignant gliomas are presented. Metabolic differences in different regions of the glioma tumor are clarified. Various types of imaging modalities, including PET and SPECT, to diagnose gliomas in general and glioblastoma in particular in patients are explained in detail. Both low-grade and high-grade gliomas are discussed. Conventional as well as fluorescent-guided resection techniques for high-grade, recurrent malignant gliomas are detailed. Impact of resection extent on outcomes in patients with high-grade gliomas is clarified. The advantage of the use of intraoperative low-field MRI in glioma surgery is explained.

Editors and Affiliations

  • , Kean University, Room 213, Library building, Union, USA

    M.A. Hayat

Bibliographic Information

  • Book Title: Tumors of the Central Nervous System, Volume 2

  • Book Subtitle: Gliomas: Glioblastoma (Part 2)

  • Editors: M.A. Hayat

  • Series Title: Tumors of the Central Nervous System

  • DOI: https://doi.org/10.1007/978-94-007-0618-7

  • Publisher: Springer Dordrecht

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer Science+Business Media B.V. 2011

  • Hardcover ISBN: 978-94-007-0617-0Published: 03 April 2011

  • Softcover ISBN: 978-94-007-3580-4Published: 29 May 2013

  • eBook ISBN: 978-94-007-0618-7Published: 03 April 2011

  • Series ISSN: 2215-096X

  • Series E-ISSN: 2215-0978

  • Edition Number: 1

  • Number of Pages: XXII, 458

  • Topics: Cancer Research, Neuroradiology, Neurosurgery, Oncology, Pathology, Surgery

Publish with us

Policies and ethics

Back to top

Search

Navigation